Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Reverse transcriptase inhibitor
Entecavir hydrate is a nucleoside analog (more specifically, a guanosine analogue) that inhibits reverse transcription, DNA replication and transcription in the viral replication process. Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection.- Masaaki Toyama, .et al. , Antimicrob Agents Chemother, 2022, Jun 21;66(6) PMID: 35604213
- Toyama M, .et al. , Virus Res, 2019, Oct 2;271:197677 PMID: 31376401
- Kazumoto Murata, .et al. , Gut, 2018, Feb; 67(2): 362-371 PMID: 27789659
- Jianfei L, .et al. , Biochem Pharmacol, 2017, Dec 15;146:224-232 PMID: 29038020
-
ntRT inhibitor
Adefovir dipivoxil is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI). It is used for treatment of hepatitis B and herpes simplex virus infection.- Ryogo Shimizu, .et al. , Hepatol Commun, 2024, Jan 5;8(1):e0351 PMID: 38180972
- Kazumoto Murata, .et al. , Gut, 2018, Feb; 67(2): 362-371 PMID: 27789659
-
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil Fumarate is employed as an anti-HIV agend and a reverse transcriptase inhibitor.- Ryogo Shimizu, .et al. , Hepatol Commun, 2024, Jan 5;8(1):e0351 PMID: 38180972
- Kazumoto Murata, .et al. , Gut, 2018, Feb; 67(2): 362-371 PMID: 27789659
-
NNRT inhibitor
MK-1439 is a non-nucleoside reverse transcriptase inhibitor -
HIV reverse transcriptase inhibitor
Dapivirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) -
NNRT inhibitor
Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor, active against wild-type HIV-1 and several nonnucleoside reverse transcriptase inhibitor-resistant strains. -
NNRT inhibitor
Delavirdine is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). -
Transcriptase inhibitor
Abacavir sulfate is a nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS. -
NNRT inhibitor
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. -
NNRT inhibitor
Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. -
NRT inhibitor
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI). -
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
nucleotide reverse transcriptase inhibitor
Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
non-nucleoside reverse transcriptase inhibitor
Delavirdine(U 90152) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI). -
nucleoside reverse transcriptase inhibitor
Emtricitabine S-oxide (Emtricitabine sulfoxide) is a major degradation product of Emtricitabine. Emtricitabine is a potent nucleoside reverse transcriptase inhibitor used for the treatment of HIV infection. -
HIV-1 reverse transcriptase inhibitor
beta-L-D4A is a nucleoside HIV-1 reverse transcriptase inhibitor. -
nucleoside reverse transcriptase (RT) inhibitor
4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside reverse transcriptase (RT) inhibitor, is an antiretroviral agent which is potent against drug-resistant HIV variants, with an EC50 of 98 nM in MT-4 cells for anti-HIV-1 activity. -
XMRV inhibitor
3'-Azido-3'-deoxy-5-methylcytidine (CS-92) is a potent xenotropic murine leukemia-related retrovirus (XMRV) inhibitor with a CC50 of 43.5 μM in MCF-7 cells. -
NRTI Inhibitor
Zidovudine is a nucleoside analog reverse-transcriptase inhibitor (NRTI), a type of antiretroviral drug used for the treatment of HIV/AIDS infection. Azidothymidine decreases CRISPR-mediated homology directed repair (HDR) efficiency. -
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
Nucleoside Reverse Transcriptase Inhibitor
Stavudine sodium is a nucleoside reverse transcriptase inhibitor (NRTI) primarily utilized for its efficacy against HIV-1 and HIV-2. This compound demonstrates the ability to inhibit mitochondrial DNA replication, reduce NLRP3 inflammasome activation, and modulate the autophagy of Amyloid-β, contributing to its therapeutic potential. Additionally, Stavudine sodium is associated with inducing apoptosis in targeted cells, making it a valuable tool in HIV research and related cellular studies. -
HIV-1 Reverse Transcriptase Inhibitor
R82913 (9-Cl-TIBO) is a selective inhibitor of HIV-1 reverse transcriptase, demonstrating significant antiviral activity against both RNA and DNA templates crucial for viral replication. This compound effectively inhibits the replication of various HIV-1 strains in CEM cells, with a median IC50 value of 0.15 μM. It serves as a valuable reagent for research applications focused on HIV therapy development and reverse transcriptase inhibition studies. -
Reverse transcriptase inhibitor
Didanosine is a reverse transcriptase inhibitor, effective against HIV and used in combination with other antiretroviral drug therapy as part of highly active antiretroviral therapy (HAART). -
NRT inhibitor
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection. -
HIV reverse transcriptase inhibitor
Tenofovir is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood. -
nucleoside analogue reverse transcriptase inhibitor
Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection. -
NNRT inhibitor
Elsulfavirine is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections. It is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. -
HIV Reverse Transcriptase Inhibitor
β-Rubromycin is a selective inhibitor of HIV-1 reverse transcriptase, exhibiting a Ki of 0.27 μM. Additionally, it demonstrates potent telomerase inhibition with an IC50 of 3 μM. β-Rubromycin effectively inhibits the proliferation of K-562 and HeLa cell lines, showing IC50 values of 19.5 µM and 22.7 µM, respectively, making it a valuable tool for research in HIV and telomerase-related studies. -
Reverse Transcriptase Inhibitor
Abacavir hydrochloride is a competitive, orally active nucleoside reverse transcriptase inhibitor primarily targeting HIV replication. This compound demonstrates significant anti-HIV activity and has been shown to exhibit anticancer effects in prostate cancer cell lines. Furthermore, Abacavir hydrochloride has the ability to cross the blood-brain barrier and suppress telomerase activity, making it a valuable reagent for research in virology and cancer biology. -
Reverse Transcriptase Inhibitor
Abacavir monosulfate is a competitive, orally active nucleoside reverse transcriptase inhibitor targeting HIV replication. It demonstrates significant antiviral activity against HIV and exhibits anticancer properties in prostate cancer cell lines. Additionally, Abacavir monosulfate is capable of crossing the blood-brain barrier and effectively suppresses telomerase activity, making it a valuable tool for research in virology and oncology. -
Nucleoside Reverse Transcriptase Inhibitor
Stavudine is an orally active nucleoside reverse transcriptase inhibitor (NRTI) that selectively targets HIV-1 and HIV-2. In addition to its antiviral properties, Stavudine inhibits mitochondrial DNA replication and has been shown to reduce NLRP3 inflammasome activation while modulating Amyloid-β autophagy. Furthermore, Stavudine is associated with the induction of apoptosis, making it a valuable tool for research in HIV treatment and cellular apoptosis mechanisms. -
HIV-1 reverse transcriptase Inhibitor
Ulonivirine is an orally active non-nucleoside inhibitor of HIV-1 reverse transcriptase, targeting the hydrophobic binding pocket adjacent to the enzyme's polymerase active site. It effectively disrupts viral replication, making it a valuable tool for research focused on HIV-1 infection and the mechanisms of antiretroviral resistance. Ulonivirine is suitable for studies aimed at understanding HIV-1 pathogenesis and developing therapeutic interventions. -
Nucleoside Reverse Transcriptase Inhibitor
Rovafovir etalafenamide is a prodrug of the adenosine nucleotide analogue GS-9148, functioning as a nucleoside reverse transcriptase inhibitor (NRTI). It demonstrates significant potency against a range of NRTI-resistant HIV-1 mutations, making it an important tool in HIV research. Its effective anti-HIV-1 activity positions it as a valuable compound for studies aimed at understanding viral resistance mechanisms and the development of therapeutic strategies. -
Nonnucleoside Reverse Transcriptase Inhibitor
IQP-0528 is a potent nonnucleoside reverse transcriptase inhibitor (NNRTI) that effectively targets HIV-1 and HIV-2. It demonstrates remarkable potency with EC50 values of 0.2 nM for HIV-1 and 100 nM for HIV-2. This compound is primarily utilized in research focused on the development of antiviral therapies and the study of HIV replication mechanisms. -
HIV-1 Reverse Transcriptase Inhibitor/μ-opioid Receptor Agonist
Corydine targets HIV-1 reverse transcriptase and the μ-opioid receptor, acting as an inhibitor with an IC50 of 356.7 μg/mL against the enzyme and an EC50 of 0.51 μM at the receptor. It exhibits antinociceptive effects through the modulation of MOR, effectively reducing acetic acid-induced writhing behavior. Corydine has also demonstrated the ability to inhibit the proliferation of various cancer cells and immune cells, making it a valuable reagent for research into HIV infection, visceral pain, and various cancers including leukemia, melanoma, bladder cancer, and colon adenocarcinoma. -
HIV-1 Reverse Transcriptase Inhibitor
Reverse transcriptase-IN-1 is a potent inhibitor of HIV-1 reverse transcriptase, classified as a diarylbenzopyrimidine (DABP) analogue. It exhibits significant antiviral activity, with effective concentration (EC50) values of 3.4 nM, 4.3 nM, and 3.6 nM against HIV-1 strains IIIB, E138K, and K103N, respectively. Additionally, it demonstrates an inhibitory concentration (IC50) of 13.7 nM on the HIV-1 reverse transcriptase enzyme, making it a valuable tool for research in HIV therapeutic development. -
Non-nucleoside Reverse Transcriptase Inhibitor
Talviraline is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets the HIV-1 reverse transcriptase enzyme, effectively hindering the replication of human immunodeficiency virus type 1 (HIV-1). By binding to a distinct site on the enzyme, Talviraline disrupts the viral replication process. This compound serves as a valuable tool for researching antiviral strategies and assessing the safety and efficacy of potential therapies against HIV-1 infection. -
HIV-1 Reverse Transcriptase Inhibitor
Atevirdine is a potent non-nucleoside HIV-1 reverse transcriptase inhibitor that specifically targets the reverse transcriptase enzyme. By inhibiting this enzyme, Atevirdine effectively disrupts viral replication, thereby reducing HIV-1 viral load. This compound is useful in research focused on HIV-1 treatment strategies and the development of antiretroviral therapies. -
Non-nucleotide HIV Reverse Transcriptase Inhibitor
Ainuovirine is a second-generation non-nucleoside HIV reverse transcriptase inhibitor (NNRTI) that targets HIV reverse transcriptase. By non-competitively binding to the enzyme, Ainuovirine effectively disrupts the reverse transcription of viral RNA, thereby inhibiting HIV replication. This compound is utilized in research focused on human immunodeficiency virus (HIV) type 1 infection. -
HIV-1 Reverse Transcriptase Inhibitor
HI-236 is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase, effectively disrupting the replication of the HIV virus. It demonstrates exceptional antiviral activity, with an IC50 value of less than 0.001 μM against wild-type HTLVIIIB. This compound is primarily utilized in HIV research, particularly in the development of antiretroviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
Urushiol (15:3) is an inhibitor of HIV-1 reverse transcriptase, demonstrating moderate inhibitory activity with an IC50 value of 55.36 μM. This compound, derived from the leaves of Rhus verniciflua, exhibits significant cytotoxicity against prostate cancer PC-3 cells and normal MRC-5 cells. Urushiol (15:3) is relevant for research into anti-HIV-1 therapies and the study of prostate cancer biology. -
Non-nucleoside Reverse Transcriptase Inhibitor
Capravirine is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) primarily targeting the HIV-1 reverse transcriptase enzyme. It demonstrates potent antiviral activity against various strains of HIV-1, including those resistant to both nucleoside/nucleotide reverse transcriptase inhibitors and other NNRTIs. Capravirine is metabolized by the cytochrome P450 enzyme CYP3A4, making it relevant for studies on drug interactions and resistance mechanisms in HIV research. -
Reverse Transcriptase Inhibitor
Inophyllum B is a potent inhibitor of HIV reverse transcriptase, exhibiting an impressive IC50 value of 38 nM. This compound effectively inhibits HIV-1 in vitro cell cultures with an IC50 of 1.4 μM. Inophyllum B is isolated from the acetone extract of the giant African snail, Achatina fulica, making it a valuable reagent for research applications focused on antiviral drug development and the mechanisms of HIV replication.
